Department of Ophthalmology & Vision Sciences, University of Toronto, St. Michael's Hospital, Canada.
Exp Eye Res. 2011 Nov;93(5):586-91. doi: 10.1016/j.exer.2011.07.006. Epub 2011 Jul 27.
Intraocular pressure (IOP) is the most important risk factor for glaucoma development and progression. Most anti-glaucoma treatments aim to lower IOP by enhancing aqueous humor drainage from the eye. Aqueous humor drainage occurs via well-characterized trabecular meshwork (TM) and uveoscleral (UVS) pathways, and recently described ciliary body lymphatics. The relative contribution of the lymphatic pathway to aqueous drainage is not known. We developed a sheep model to quantitatively assess lymphatic drainage along with TM and UVS outflows. This study describes that model and presents our initial findings. Following intracameral injection of (125)I-bovine serum albumin (BSA), lymph was continuously collected via cannulated cervical lymphatic vessels and the thoracic lymphatic duct over either a 3-h or 5-h time period. In the same animals, blood samples were collected from the right jugular vein every 15 min. Lymphatic and TM drainage were quantitatively assessed by measuring (125)I-BSA in lymph and plasma, respectively. Radioactive tracer levels were also measured in UVS and "other" ocular tissue, as well as periocular tissue harvested 3 and 5 h post-injection. Tracer recovered from UVS tissue was used to estimate UVS drainage. The amount of (125)I-BSA recovered from different fluid and tissue compartments was expressed as a percentage of total recovered tracer. Three hours after tracer injection, percentage of tracer recovered in lymph and plasma was 1.64% ± 0.89% and 68.86% ± 9.27%, respectively (n = 8). The percentage of tracer in UVS, other ocular and periocular tissues was 19.87% ± 5.59%, 4.30% ± 3.31% and 5.32% ± 2.46%, respectively. At 5 h (n = 2), lymphatic drainage was increased (6.40% and 4.96% vs. 1.64%). On the other hand, the percentage of tracer recovered from UVS and other ocular tissue had decreased, and the percentage from periocular tissue showed no change. Lymphatic drainage increased steadily over the 3 h post-injection period, while TM drainage increased rapidly - reaching a plateau at 30 min. This quantitative sheep model enables assessment of relative contributions of lymphatic drainage, TM and UVS outflows, and may help to better understand the effects of glaucoma agents on outflow pathways.
眼压 (IOP) 是青光眼发展和进展的最重要风险因素。大多数抗青光眼治疗旨在通过增强房水从眼睛中的排出来降低 IOP。房水通过特征良好的小梁网 (TM) 和葡萄膜巩膜 (UVS) 途径以及最近描述的睫状体淋巴管排出。淋巴途径对房水排出的相对贡献尚不清楚。我们开发了一种绵羊模型来定量评估淋巴管与 TM 和 UVS 流出物的引流。本研究描述了该模型,并介绍了我们的初步发现。在房内注射 (125)I-牛血清白蛋白 (BSA) 后,通过套管颈淋巴导管连续收集淋巴,在 3 小时或 5 小时的时间内通过胸导管收集。在相同的动物中,每隔 15 分钟从右颈静脉采集血液样本。通过分别测量淋巴和血浆中的 (125)I-BSA 来定量评估淋巴和 TM 引流。还测量了 UVS 和“其他”眼组织以及注射后 3 和 5 小时收获的眶周组织中的放射性示踪剂水平。从 UVS 组织中回收的示踪剂用于估计 UVS 引流。从不同的液体和组织隔室中回收的 (125)I-BSA 的量表示为总回收示踪剂的百分比。在示踪剂注射后 3 小时,淋巴和血浆中回收的示踪剂百分比分别为 1.64%±0.89%和 68.86%±9.27%(n=8)。UVS、其他眼组织和眶周组织中的示踪剂百分比分别为 19.87%±5.59%、4.30%±3.31%和 5.32%±2.46%(n=2)。在 5 小时时(n=2),淋巴引流增加(6.40%和 4.96%比 1.64%)。另一方面,从 UVS 和其他眼组织中回收的示踪剂百分比降低,而从眶周组织中回收的示踪剂百分比没有变化。淋巴引流在注射后 3 小时内稳步增加,而 TM 引流迅速增加-在 30 分钟时达到平台期。这种定量绵羊模型能够评估淋巴引流、TM 和 UVS 流出物的相对贡献,并且可能有助于更好地了解青光眼药物对流出途径的影响。